secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2026-01-27T23:59:59+00:00
Accession:  0001193125-26-024375
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology CEO and CFO step down; onvansertib Phase 2 hits 72.2% ORR in mCRC
--------------------------------------------------------------------------------

- CEO Mark Erlander and CFO James Levine stepped down; Mani Mohindru named interim CEO, Brigitte Lindsay promoted to CAO.
- Phase 2 CRDF-004: onvansertib 30mg + FOLFIRI/bev showed 72.2% ORR vs 43.2% SoC (p=0.051) and PFS HR 0.37 vs SoC (p=0.048).
- Company selected 30mg dose of onvansertib with FOLFIRI/bev for registrational program; plans to initiate later in 2026 after FDA consultation.
- Final data and registrational plans expected in H1 2026; onvansertib well-tolerated with no additive toxicity.
- Conference call today at 8:30 a.m. ET to discuss results and strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000119312526024375/0001193125-26-024375-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000119312526024375/crdf-20260127.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-024375

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer